Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAdamis Pharmaceuticals Corporation Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2023 | Q3 2023 | N/A | $0.05 | N/A | N/A | $9.06 M |
| 08/18/2023 | Q2 2023 | N/A | -$3.34 | N/A | N/A | $6.95 K |
| 05/15/2023 | Q1 2023 | N/A | $0.03 | N/A | N/A | $1.45 M |
| 03/16/2023 | Q4 2022 | N/A | -$1.59 | N/A | N/A | $2.15 M |
| 11/14/2022 | Q3 2022 | N/A | -$2.05 | N/A | N/A | $1.51 M |
| 08/10/2022 | Q2 2022 | $2.80 | -$3.92 | -6.72 | N/A | $39.85 K |
| 05/16/2022 | Q1 2022 | $2.10 | -$4.84 | -6.94 | N/A | $1.15 M |
| 03/31/2022 | Q4 2021 | $0.05 | -$4.12 | -4.17 | N/A | $-1,159,435 |
| 11/22/2021 | Q3 2021 | $4.20 | -$5.81 | -10.01 | N/A | $759.96 K |
| 11/22/2021 | Q2 2021 | $4.20 | -$4.38 | -8.58 | N/A | $4.01 M |
| 11/22/2021 | Q1 2021 | $4.20 | -$8.32 | -12.52 | N/A | $4.11 M |
| 04/15/2021 | Q4 2020 | N/A | -$15.19 | N/A | N/A | $3.64 M |
| 11/09/2020 | Q3 2020 | $2.80 | -$6.89 | -9.69 | N/A | $4.30 M |
| 08/17/2020 | Q2 2020 | $4.90 | -$10.68 | -15.58 | N/A | $3.93 M |
| 05/18/2020 | Q1 2020 | $3.50 | -$10.81 | -14.31 | N/A | $4.66 M |
| 03/30/2020 | Q4 2019 | $2.56 | -$6.44 | -9 | N/A | $5.54 M |
| 11/12/2019 | Q3 2019 | $4.20 | -$8.71 | -12.91 | N/A | $5.90 M |
| 08/08/2019 | Q2 2019 | $8.39 | -$11.39 | -19.78 | N/A | $5.76 M |
| 05/09/2019 | Q1 2019 | $11.89 | -$13.15 | -25.04 | N/A | $4.91 M |
| 03/15/2019 | Q4 2018 | $13.29 | -$18.93 | -32.22 | N/A | $4.15 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Adamis Pharmaceuticals Corporation Earnings: FAQ's
Adamis Pharmaceuticals Corporation has not confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, November 12th, 2023 based offlast year's report dates.
In the previous quarter, Adamis Pharmaceuticals Corporation (:ADMP) reported $4.2 earnings per share (EPS) to beat the analysts' consensus estimate of $2.8 by $1.4.
The conference call for Adamis Pharmaceuticals Corporation's latest earnings report can be listened to online.
The conference call transcript for Adamis Pharmaceuticals Corporation's latest earnings report can be read online.
Adamis Pharmaceuticals Corporation (:ADMP) has a recorded annual revenue of $4.76 M.
Adamis Pharmaceuticals Corporation (:ADMP) has a recorded net income of $-26,199,406.Adamis Pharmaceuticals Corporation has generated $-12.24 earnings per share over the last four quarters.
Adamis Pharmaceuticals Corporation (:ADMP) has a price-to-earnings ratio of -0.06 and price/earnings-to-growth ratio is -0.